Location · Seattle, WA
Clinical trials in Seattle, WA
401 recruiting studies have a site in the Seattle area, and 104 of them accept healthy volunteers. The area includes Bellevue, Kirkland, Redmond, Renton, Everett, Tacoma and nearby cities.
401 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Scottsdale, AZ + 33 other US sites
- Eligibility basics
- Ages 1–25
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics, Inc.
- Location
- San Francisco, CA + 20 other US sites
- Eligibility basics
- Ages 5–40
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Merck Sharp & Dohme LLC
- Location
- Los Angeles, CA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Guntersville, AL + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Sanofi
- Location
- San Francisco, CA + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC
- Location
- Anaheim, CA + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2/Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Novartis Pharmaceuticals
- Location
- Oakland, CA + 17 other US sites
- Eligibility basics
- Ages 0 mo–100
- RecruitingPhase 2
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
Zomagen Biosciences Ltd.
- Location
- La Jolla, CA + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
- Location
- Cullman, AL + 53 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Phoenix, AZ + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals
- Location
- St Louis, MO + 8 other US sites
- Eligibility basics
- Ages 2–100
- Recruiting
ELEVATE High-Risk PCI Pivotal Study
Magenta Medical Ltd.
- Location
- Phoenix, AZ + 32 other US sites
- Eligibility basics
- Ages 18–88
- RecruitingPhase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Incyte Corporation
- Location
- Duarte, CA + 6 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
UCB Biopharma SRL
- Location
- Miami, FL + 6 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
W.L.Gore & Associates
- Location
- Phoenix, AZ + 20 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Phoenix, AZ + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Chandler, AZ + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Scottsdale, AZ + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company
- Location
- Birmingham, AL + 17 other US sites
- Eligibility basics
- Ages 18+ · Women only